ASCO 2019 ANNUAL MEETING

ASCO 2019 ANNUAL MEETING

INTERVIEW WITH EVAN YU
Management of mCRPC using Sipuleucel-T

VIEW ALL mCRPC VIDEOS

ASCO 2019 ANNUAL MEETING

ASCO 2019 ANNUAL MEETING

INTERVIEW WITH JACOB BERCHUCK & MARY-ELLEN TAPLIN
Genetic Risk in Prostate Cancer

VIEW ALL PROSTATE CANCER VIDEOS

ASCO 2019 ANNUAL MEETING

ASCO 2019 ANNUAL MEETING

INTERVIEW WITH KARIM FIZAZI
ARAMIS Trial in Prostate Cancer: Impact of Darolutamide on Pain and Quality of Life

VIEW ALL nmCRPC VIDEOS

EAU 2019 ANNUAL MEETING

EAU 2019 ANNUAL MEETING

INTERVIEW WITH THOMAS POWLES
Immunotherapy in the Peri-Operative Setting for Bladder Cancer

VIEW ALL BLADDER CANCER VIDEOS

Videos
State-of-the-industry video lectures by leading urology experts
Featured Videos

#AUA14 - Validation of a 46-gene cell cycle progression (CCP) RNA signature for predicting prostate cancer death in a conservatively managed watchful waiting needle biopsy cohort - Session Highlights

ORLANDO, FL USA (UroToday.com) - Prostate cancer biomarkers have tremendous potential to influence decisions regarding treatment and active surveillance. The CCP (cell cycle progression) score is a 46-gene expression level biomarker already known to be a robust predictor of prostate cancer outcomes. Dr. Jack Cuzick and colleagues performed validation of the CCP score and a combined clinical risk score (CCR + clinical variables) for predicting disease-specific mortality (DSM) in a cohort of conservatively managed patients diagnosed by needle biopsy. CCP score was calculated by extracting mRNA from prostate needle biopsy specimens in 757 men diagnosed with clinically localized prostate cancer. The primary endpoint was disease specific mortality, with a mean clinical follow-up of 10.6 years.

auaA change in the CCP score from the 25th to 75th percentile increased the hazard of DSM by 2.3 fold. Following multivariable analysis, CCP remained associated with an increased risk of DSM (HR 1.86). Of the variables examined, including CAPRA score and clinical parameters, CCP was the most significant independent prognostic factor for DSM. The CCR score was also predictive of DSM, while addition of CAPRA did not add significant prognostic information to the CCR score. CCP provides significant pre-treatment prognostic information for patients managed conservatively with active surveillance or watchful waiting, and is a valuable addition for the informed management of newly diagnosed PC patients.

Presented by Peter T. Scardino, MD, FACS at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

Click HERE to listen to Peter Scardino, MD, FACS discuss the study.

Click HERE to view the poster from this session.

Memorial Sloan Kettering Cancer Center, New York, NY USA

Written by Jeffrey J. Tomaszewski, MD, medical writer for UroToday.com.

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 4 Issue 1

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe